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The risk of bleeding in the setting of anticoagulant therapy continues to be re-evaluated following the
introduction of a new generation of direct oral anticoagulants (DOACs). Interruption of DOAC therapy and
supportive care may be sufﬁcient for the management of patients who present with mild or moderate
bleeding, but in those with life-threatening bleeding, a speciﬁc reversal agent is desirable. We review the
phase 3 clinical studies of dabigatran, rivaroxaban, apixaban, and edoxaban in patients with nonvalvular
atrial ﬁbrillation, in the context of bleeding risk and management.
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0RivaroxabanThe vitamin K antagonists (VKAs), such as warfarin, have
been the standard and indeed, only, option for oral antico-
agulant therapy for decades. However, their use requires
routine coagulation monitoring because genetic variation
and interactions between warfarin and diet, other drugs, and
comorbidities produce variable and unpredictable antico-
agulant effects.1-3 The time in therapeutic range is awork was supported by Boehringer Ingelheim Phar-
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Elsevier Inc. This is an open access article under the CC BY
.1016/j.amjmed.2016.06.003determinant of the efﬁcacy and safety of warfarin.4 In 1
representative study, 62% of warfarin-treated patients with
nonvalvular atrial ﬁbrillation (NVAF) who were admitted to
the emergency department for ischemic strokes had inter-
national normalized ratios (INRs) that were outside of the
desired therapeutic range.5
The new generation of direct oral anticoagulants (DOACs)
offers important advantages over warfarin, but the risk of
bleeding with these drugs—as with all anticoagulants—re-
mains an ongoing safety concern. The DOACs currently
approved by the U.S. Food and Drug Administration (FDA)
include the direct thrombin inhibitor dabigatran, which was
approved in 2010, and the more recently introduced direct
factor Xa (FXa) inhibitors rivaroxaban, apixaban, and edox-
aban. In contrast to warfarin, DOACs have a more rapid onset,
predictable anticoagulant effect, shorter half-life,6-9 and few
drugedrug and dietary interactions.10-13 Hence, they can be
given in ﬁxed doses without routine coagulation monitoring.
The severity of bleeding events with anticoagulant use
ranges from minor bleeding to life-threatening intracranial
hemorrhages (ICHs) or exsanguinating hemorrhages. Sup-
portive measures for bleeding management in anti-
coagulated patients vary depending on the setting and
speciﬁc on-board therapy. Identifying the optimal manage-
ment strategy is a critical component of bleeding manage-
ment. The landscape has recently changed with the
introduction of a speciﬁc rapidly acting reversal agent for-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1 Primary Safety Outcome Data from Phase 3 Studies of DOACs vs Warfarin by Type of Bleeding
Primary Safety Outcome
(Percentage of Patients
with an Adverse Event)*
RE-LY18,† ROCKET AF19, 20 ARISTOTLE21 ENGAGE-AF TIMI 4822
Dabigatran
150 mg
(n ¼ 6076)
Dabigatran
110 mg
(n ¼ 6015)
Warfarin
(n ¼ 6022)
Rivaroxaban
(n ¼ 7111)
Warfarin
(n ¼ 7125)
Apixaban
(n ¼ 9088)
Warfarin
(n ¼ 9052)
Edoxaban 60 mg
(n ¼ 7012)
Edoxaban 30 mg
(n ¼ 7002)
Warfarin
(n ¼ 7012)
Major bleeding 3.11% per y 2.71% per y 3.36% per y 3.6% per y 3.4% per y 2.13% per y 3.09% per y 2.75% per y 1.61% per y 3.43% per y
Hazard ratio (95% CI) 0.93 (0.81-1.07) 0.80 (0.69-0.93) — 1.04 (0.90-1.20) — 0.69 (0.60-0.80) — 0.80 (0.71-0.91) 0.47 (0.41-0.55) —
P-value .31 .003 .58 <.001 <.001 <.001
Intracranial bleeding 0.30% per y 0.23% per y 0.74% per y 0.5% per y 0.7% per y 0.33% per y 0.80% per y 0.39% per y 0.26% per y 0.85% per y
Hazard ratio (95% CI) 0.40 (0.27-0.60) 0.31 (0.20-0.47) — 0.67 (0.47-0.93) — 0.42 (0.30-0.58) — 0.47 (0.34-0.63) 0.30 (0.21-0.43) —
P-value <.001 <.001 .02 <.001 <.001 <.001
Gastrointestinal bleeding 1.51% per y 1.12% per y 1.02% per y 2.00% per y 1.24% per y 0.76% per y 0.86% per y 1.51% per y 0.82% per y 1.23% per y
Hazard ratio (95% CI) 1.50 (1.19-1.89) 1.10 (0.86-1.41) — 1.61 (1.30-1.99) — 0.89 (0.70-1.15) — 1.23 (1.02-1.50) 0.67 (0.53-0.83) —
P-value <.001 .43 <.0001 .37 .03 <.001
ARISTOTLE ¼ Apixaban for Reduction in STroke and Other ThromboemboLic Events in Atrial Fibrillation; CI ¼ conﬁdence interval; DOAC ¼ direct or anticoagulant; ENGAGE-AF TIMI 48 ¼ Effective aNti-
coaGulation with factor Xa next GEneration in Atrial FibrillationeThrombolysis in Myocardial Infarction study 48; RE-LY ¼ Randomized Evaluation of Long-t m anticoagulation therapY; ROCKET AF ¼ Rivaroxaban
Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation.
*Data are presented as reported in each publication. Proportion of patients with an adverse event is described as an event rate (percentage/year) 1 1,22 or event rate number/100 patient-years. 19,20
†Rates of the primary safety outcomes from the RE-LY trial are reported as relative risk, not hazard ratios.
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Table 2 Dosage and Administration of DOACs for Patients with
NVAF According to Renal Function*
Drug Renal Function (CrCl)
Dosage and
Administration
Dabigatran
etexilate10
>30 mL/min 150 mg BID
15-30 mL/min 75 mg BID
<15 mL/min or
on dialysis
Not provided†
Rivaroxaban13 >50 mL/min 20 mg QD with
evening meal
15-50 mL/min 15 mg QD with
evening meal
<15 mL/min Not provided‡
Apixaban11 No dose adjustment
is recommended for
patients with RI alone
(including patients with
ESRD [<15 mL/min] and
maintained on hemodialysis)
5 mg BID
For patients with at
least 2 of the following
characteristics: 80 y
of age, weight 60 kg,
or serum creatinine
1.5 mg/dL
2.5 mg BID
Edoxaban12 >95 mg/dL Avoid use
>50 to 95 mL/min 60 mg QD
15-50 mL/min 30 mg QD
<15 mL/min Not recommended
BID ¼ twice daily; CrCl ¼ creatinine clearance; DOAC ¼ direct oral
anticoagulant; NVAF ¼ nonvalvular atrial ﬁbrillation; QD ¼ once daily;
RI ¼ renal impairment.
*Information in this table is based on the U.S. prescribing infor-
mation for the available agents. Please see individual prescribing in-
formation for warnings and precautions.
†Dosing recommendations cannot be provided for patients with
CrCl <15 mL/min or on dialysis.10
‡Clinical efﬁcacy and safety studies with Xarelto did not enroll pa-
tients with end-stage renal disease on dialysis.13
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review the phase 3 clinical studies of dabigatran, rivarox-
aban, apixaban, and edoxaban as compared with warfarin in
the context of bleeding risk and management. This article
focuses on studies performed in patients with NVAF.
Postmarketing and “real-world” data are presented by Vil-
lines et al15 in this special issue. We will also brieﬂy discuss
the current strategies for assessing coagulation and general
measures for managing DOAC bleeding. Discussions of
speciﬁc DOAC reversal agents are presented by Pollack16
and Milling et al17, elsewhere in this special issue.BLEEDING RISKS IN PHASE 3 NVAF TRIALS OF
DOACS VS WARFARIN
In phase 3 clinical trials, dabigatran, rivaroxaban, apixaban,
and edoxaban were compared with VKAs for the preventionof stroke or systemic embolism in NVAF. The incidence of
major bleeding or a composite of major and nonmajor
clinically relevant bleeding were the primary safety end
points in these trials.Dabigatran
In the Randomized Evaluation of Long-term anticoagulation
therapY (RE-LY) study, 18,113 patients who had NVAF and
risk of stroke were randomized to dabigatran 110 mg
twice daily or 150 mg twice daily, or warfarin (adjusted doses
with a target INR of 2-3), and were followed for a median of
2.0years.18 In theprimarypublication of theRE-LYstudy, rates
of major bleeding were 3.11% per year in the dabigatran
150-mg-twice-daily group (relative risk 0.93; 95% conﬁdence
interval [CI], 0.81-1.07; P ¼ .31) and 2.71% per year in the
dabigatran 110-mg-twice-daily group (relative risk 0.80; 95%
CI, 0.69-0.93; P ¼ .003) vs 3.36% per year in the warfarin
group.18 Dabigatran 150mg twice daily and 110mg twice daily
reduced the relative risk of intracranial bleeding (both doses P
<.001), and only dabigatran 150 mg twice daily increased the
relative risk ofmajor gastrointestinal (GI) bleeding (P<.001)vs
warfarin (Table 1).18-22 After completion of the study, addi-
tional primary efﬁcacy and safety outcome events were identi-
ﬁed, and the rates ofmajorbleedingwere revised to3.32%in the
dabigatran 150 mg twice-daily group (relative risk 0.93; 95%
CI, 0.81-1.07; P ¼ .32) and 2.87% in the dabigatran 110-mg-
twice-daily group (relative risk 0.80; 95% CI, 0.70-0.93; P ¼
.003) vs 3.57% in the warfarin group.23 Inclusion of the newly
identiﬁed events did not change the study conclusions.23
Overall, these results contributed to the FDA approval of
dabigatran etexilate for prevention of stroke and systemic em-
bolism in patients with NVAF.10 As dabigatran etexilate is
predominantly eliminated in the urine (80% renal excretion),10
renal impairment can increase the exposure to dabigatran, and
thus, dose adjustment may be considered in this patient popu-
lation. For patients with a creatinine clearance (CrCl) of 15-30
mL/min, the recommended dosage of dabigatran etexilate in the
United States is 75 mg twice daily. Patients with a
CrCl of30mL/minwere excluded from theRE-LY trial24 and
dosing recommendations for patients with a CrCl of <15 mL/
min or on dialysis are not provided10 (Table 2). Outside of the
United States, dabigatran 110 mg twice daily is recommended
for patients deemed to be at risk of stroke, including: elderly
patients (age 80 years), concomitant use of interacting drugs
(eg, verapamil), high bleeding risk (HAS-BLED score 3), or
moderate renal impairment (30-50 mL/min).25-27
In a subgroup analysis of the RE-LY study, the risk of
major bleeding was assessed according to age.28 Dabigatran
110 mg twice daily compared with warfarin was associated
with a lower risk of major bleeding in younger patients
(aged <75 years; 1.89% vs 3.04%; P <.001) and a
similar risk in older patients (aged 75 years; 4.43% vs
4.37%; P ¼ .89). Dabigatran 150 mg twice daily compared
with warfarin was associated with a lower risk of major
bleeding in younger patients (2.12% vs 3.04%; P <.001)
and a trend toward a higher risk of major bleeding in older
S36 The American Journal of Medicine, Vol 129, No 11A, November 2016patients (5.10% vs 4.37%; P ¼ .07). The similar or higher
risk of major bleeding was driven by rates of extracranial
bleeding, primarily GI bleeding; the risk of ICH was lower
with both doses of dabigatran compared with warfarin,
irrespective of age. In a separate subgroup analysis of the
RE-LY cohort, the incidence of ICH during anticoagulation
therapy was evaluated by site (intracerebral, subdural, or
subarachnoid), risk factors, and outcomes.29 The relative
risk of intracerebral hemorrhage was reduced with dabiga-
tran 150 mg twice daily (relative risk 0.23; 95% CI,
0.12-0.45; P <.001) and dabigatran 110 mg twice daily
(relative risk 0.30; 95% CI, 0.16-0.54; P <.001) compared
with warfarin. The relative risk of subdural hemorrhages
was only reduced with dabigatran 110 mg twice daily
compared with warfarin (relative risk 0.27; 95% CI,
0.12-0.55; P <.001). Dabigatran 150 mg twice daily and
110 mg twice daily did not signiﬁcantly reduce the risk of
subarachnoid hemorrhages compared with warfarin. Mor-
tality following ICH was similar in patients treated with
dabigatran 150 mg twice daily (35%), dabigatran 110 mg
twice daily (41%), or warfarin (36%).
Bleeding management and outcomes were evaluated in
a separate analysis of the RE-LY cohort.30 More patients
in the dabigatran 150-mg-twice-daily (61.4%) vs warfarin
group (49.9%) were treated with blood transfusions
(P <.001), and fewer patients in both dabigatran groups
were administered fresh frozen plasma (FFP) (dabigatran
150 mg twice daily, 21.6% and dabigatran 110 mg twice
daily, 17.8%) vs warfarin (30.2%; P < .005 and P < .001,
respectively). The proportion of major bleeding
events requiring hospitalization was similar between
dabigatran 110 mg twice daily and 150 mg twice daily
compared with warfarin (51.2%, 61.8%, and 56.5%,
respectively).Rivaroxaban
In the Rivaroxaban Once daily oral direct factor Xa
inhibition compared with vitamin K antagonism for pre-
vention of stroke and Embolism Trial in Atrial Fibrillation
(ROCKET AF), 14,264 patients with NVAF who were at
moderate-to-high risk for stroke were randomized to rivar-
oxaban or warfarin and followed for a median of 1.94
years.19 Patients received ﬁxed-dose rivaroxaban (20 mg
once daily or 15 mg once daily in patients with a CrCl of
30-49 mL/min) or adjusted doses of warfarin (target INR of
2-3). The rates of any major bleeding event (number per 100
patient-years) were similar between the rivaroxaban group
(3.6) and the warfarin group (3.4) (hazard ratio [HR] 1.04;
95% CI, 0.90-1.20; P ¼ .58).19 Rivaroxaban compared with
warfarin reduced the rate of ICH (HR 0.67; 95% CI,
0.47-0.93; P ¼ .02)19,20 and increased the rate of major GI
bleeding (HR 1.61; 95% CI, 1.30-1.99, P <.001)20
(Table 1). Based on these safety and efﬁcacy data, the
FDA approved rivaroxaban 20 mg once daily for NVAF
patients with a CrCl of >50 mL/min and 15 mg once
daily for those with a CrCl of 15-50 mL/min13 (Table 2).In a separate analysis of the ROCKET AF cohort,
baseline factors that were independently associated with
major bleeding were: age, sex, diastolic blood pressure,
history of chronic obstructive pulmonary disease, prior GI
bleeding, prior aspirin use, and anemia.31 The relative risk
of major bleeding with rivaroxaban vs warfarin treatment
was similar regardless of age, whereas the risk of ICH was
reduced irrespective of age. Rivaroxaban was associated
with reductions in various subtypes of ICH, including
intraparenchymal, intraventricular, and subdural compared
with warfarin (all P <.05; no HRs provided). Patients with a
history of GI bleeding who were treated with rivaroxaban
were at higher risk of major bleeding than those treated with
warfarin (HR 2.33; 95% CI, 1.39-3.88; interaction
P ¼ .002), whereas the risk of GI bleeding was similar
between rivaroxaban and warfarin if there was no history of
GI bleeding (HR 1.00; 95% CI, 0.86-1.16).
Bleeding management and outcomes were evaluated in a
separate analysis of the ROCKET AF cohort.32 Among
patients who experienced major bleeding, rivaroxaban
compared with warfarin was associated with less frequent
use of FFP (45 vs 81 units; odds ratio 0.43; 95% CI,
0.29-0.66; P <.0001) and prothrombin complex concentrate
(PCC) (4 [0.9%] vs 9 [2.2%] patients). Outcomes after
major bleeding, including duration of hospitalization (5 days
vs 6 days) and all-cause death (20.4% vs 26.1%; HR 0.688;
95% CI, 0.455-1.042) were similar among patients treated
with rivaroxaban or warfarin.Apixaban
In the Apixaban for Reduction In STroke and
Other ThromboemboLic Events in Atrial Fibrillation
(ARISTOTLE) study, 18,201 patients with AF and at least
one additional risk factor for stroke were randomized to
apixaban or dose-adjusted warfarin (target INR 2-3) and
followed for a median of 1.8 years.21 Apixaban was
administered twice daily as ﬁxed doses of either 5 mg or
2.5 mg according to age, body weight, and serum creatinine
level. The rates of major bleeding were 2.13% per year in
the apixaban group vs 3.09% per year in the warfarin group
(HR 0.69; 95% CI, 0.60-0.80; P <.001). The rate of intra-
cranial bleeding was reduced with apixaban compared with
warfarin (0.33% vs 0.80% per year; HR 0.42; 95% CI,
0.30-0.58; P <.001). In contrast, the rate of GI bleeding did
not differ between apixaban and warfarin (0.76 vs 0.86%
per year; HR 0.89; 95% CI, 0.70-1.15; P ¼ .37) (Table 1).21
These safety data contributed to the FDA approval of
apixaban 5 mg twice daily for patients with NVAF.11
Apixaban 2.5 mg twice daily is recommended for patients
with at least 2 of the following characteristics: 80 years of
age, weight 60 kg, or serum creatinine 1.5 mg/dL
(Table 2).
In a separate analysis, Hylek et al33 evaluated clinical
outcomes associated with major bleeding in patients
enrolled in ARISTOTLE. Baseline factors that were inde-
pendently associated with major hemorrhage were: older
Table 3 Available Assays for Measurement of DOAC Activity
Useful Laboratory Test Dabigatran Rivaroxaban Apixaban Edoxaban
Strong ECT Chromogenic
anti-FXa
Chromogenic
anti-FXa
Chromogenic
anti-FXa
TT/dTT PT* PT
aPTT
Weak PT/INR
aPTT ¼ activated partial thromboplastin time; DOAC ¼ direct oral anticoagulant; dTT ¼ dilute thrombin time; ECT ¼ ecarin clotting time; FXa ¼ factor
Xa; INR ¼ international normalized ratio; PT ¼ prothrombin time; TT ¼ thrombin time.
*PT reagent neoplastin has the most linear correlation.
Table 4 Currently Available Blood Products for Rescue Man-
agement in DOAC Bleeding (Rivaroxaban and Apixaban)
Product Factors Dosage and Administration*
3-Factor PCC II, IX, X 50 U/kg, IV
May repeat Q 12 h
4-Factor PCC II, VII, IX, X,
Proteins C and S
50 U/kg, IV;
One time dose
DOAC ¼ direct oral anticoagulant; IV ¼ intravenous; PCC ¼ pro-
thrombin complex concentrate; Q 12 h ¼ every 12 hours.
*Dosage and administration recommendations are based on clinical
information25, 43-45 and expert opinion, as the use of PCCs to reverse the
anticoagulant effects of DOACs is not an approved indication in the
United States.46,47
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attack, diabetes, a lower CrCl (<85 mL/min/1.73 m2),
decreased hematocrit level (<45%), use of aspirin therapy,
and use of nonsteroidal anti-inﬂammatory drugs.33 Adverse
events following major extracranial hemorrhage occurred
less frequently in the apixaban than in the warfarin group,
including fewer hospitalizations (1.05% vs 1.41% per 100
patient-years; HR 0.75; 95% CI, 0.61-0.92; P ¼ .0052) and
fewer transfusions (0.89% vs 1.25% per 100 patient-years;
HR 0.71; 95% CI, 0.57-0.89; P ¼ .0025).33 In addition,
death within 30 days following major hemorrhage occurred
half as often with apixaban vs warfarin (36 vs 71 events; HR
0.50; 95% CI, 0.33-0.74; P <.001).
Edoxaban
In the Effective aNticoaGulation with factor xA next GEner-
ation in Atrial Fibrillation-Thrombolysis in Myocardial
Infarction study 48 (ENGAGE-AF TIMI 48), 21,105 patients
with moderate-to-high-risk AF were randomized to warfarin,
high-dose (HD) edoxaban (60 mg) once daily or low-dose
(LD) edoxaban (30 mg) once daily, and followed for a me-
dian of 2.8 years.22 The dose of edoxabanwas reduced by 50%
in patients with an estimated CrCl of 30-50 mL/min, body
weight of 60 kg, or the concomitant use of potent P-glyco-
protein inhibitors at baseline or during the course of the study.
The annualized rate ofmajor bleeding in patients receivingHD
edoxaban was 2.75% (HR 0.80; 95% CI, 0.71-0.91; P<.001)
and 1.61% in patients receiving LD edoxaban (HR 0.47; 95%
CI, 0.41-0.55;P<.001), comparedwith 3.43% in thewarfarin
group. Rates of ICHwere reducedwith HD edoxaban (0.39%;
HR 0.47; 95% CI, 0.34-0.63) and LD edoxaban (0.26%; HR
0.30; 95% CI, 0.21-0.43) relative to warfarin (0.85%; both
doses P <.001). Gastrointestinal bleeding occurred more
frequentlywithHDedoxaban (1.51%;HR1.23; 95%CI, 1.02-
1.50; P ¼ .03) and less frequently with LD edoxaban than
warfarin (0.82% vs 1.23%; HR 0.67; 95% CI, 0.53-0.83; P
<.001) (Table 1). Based on these data, edoxaban 60 mg once
daily was approved by the FDA for patients with NVAF and a
CrCl of >50 to 95 mL/min.12 A dose adjustment to edox-
aban 30mg once daily is recommended in patients with a CrCl
of 15-50 mL/min (Table 2).In a subgroup analysis, both doses of edoxaban
were associated with reductions in various subtypes of
ICH, including parenchymal, subarachnoid, and subdural
or epidural bleeds.34 Both edoxaban doses also reduced
the composite outcome of death, nonfatal stroke, or
ICH (HR 0.88; P ¼ .003 for HD edoxaban, and HR, 0.90;
P ¼ .021 for LD edoxaban) compared with warfarin. In a
separate subgroup analysis, Ruff et al35 reported that
reducing edoxaban dose based on prespeciﬁed clinical fac-
tors (deﬁned above) maintained the anticoagulant efﬁcacy of
edoxaban and was associated with a reduced risk of major
bleeding compared with warfarin.
In summarizing all the above studies, major bleeding risk
was reduced with apixaban (5 or 2.5 mg) twice daily,
edoxaban (60 mg and 30 mg) once daily, and dabigatran
110 mg twice daily vs warfarin, and rivaroxaban
(20 or 15 mg) once daily and dabigatran 150 mg twice daily
had a similar bleeding risk vs warfarin. The risk of major GI
bleeding was similar with apixaban (5 or 2.5 mg) twice daily
and dabigatran 110 mg twice daily vs warfarin, and
increased with rivaroxaban (20 or 15 mg) once daily and
dabigatran 150 mg twice daily vs warfarin. The risk of GI
bleeding with edoxaban was greater with edoxaban 60 mg
once daily and lower with edoxaban 30 mg once daily.
Intracranial bleeding risk was reduced with all DOACs that
were compared with warfarin.
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MANAGEMENT OF DOAC BLEEDING
DOACs do not require routine monitoring18,19,21,22 as is
necessary with warfarin, but laboratory measurement of
blood levels or anticoagulant activity may be helpful during
an emergent bleeding situation or in a number of other
settings. Liquid chromatography tandem mass spectrometry
is a quantitative method of measuring DOAC concentration
but is not a practical option for routine clinical use. In some
circumstances, commonly available coagulation tests such
as the activated partial thromboplastin time (aPTT),
prothrombin time, and thrombin time (TT) can provide
qualitative assessments of the presence or absence of an
anticoagulant effect, but their sensitivity differs depending
on the agent. Speciﬁc assays, including dilute thrombin
time, ecarin clotting time (ECT), ecarin chromogenic assays,
and chromogenic anti-FXa assays can be used to quantify
drug levels accurately but are not yet widely available in the
United States.36-39 Applications of these assays to speciﬁc
DOACs are summarized in Table 3 and will be discussed in
further detail by Levy et al40 in this special issue.Rescue Therapies for Life-Threatening Bleeding
Events in DOAC-Anticoagulated Patients
Until recently there was no DOAC-speciﬁc reversal agent
available, and nonspeciﬁc hemostatic products have been used
in bleeding management of DOAC-anticoagulated patients.
Strategies for managing bleeding complications with nonspe-
ciﬁc hemostatic agents are different in patients anticoagulated
with DOACs compared with warfarin. In the presence of
warfarin, which has a long half-life, nonspeciﬁc hemostatic
products including FFP and PCCs replenish clotting factors
and their effects can be sustained with the addition of
vitamin K.41 In contrast, circulating DOACs will also inhibit
the exogenous clotting factors, and FFP may not effectively
counteract DOAC-mediated anticoagulation.27,42 The PCCs
contain high concentrations of vitamin K-dependent coagula-
tion factors (Table 4),27, 43-47 whereas recombinant FVIIa
(rFVIIa) contains high concentrations of coagulation FVIIa.
Vitamin K does not reverse the anticoagulant effect of
DOACs.10-13 Antiﬁbrinolytic agents can be used in patients
with bleeding,48 but their efﬁcacy is unproven.43
The nonactivated PCCs, including 4-Factor PCC and
3-Factor PCC may be effective for management of bleeding
in patients anticoagulated with apixaban,11 dabigatran,10
rivaroxaban,13 or edoxaban.49,50 The PCCs raise the levels
of coagulation factors that have been inhibited by DOACs.
Their use in patients treated with DOACs is primarily
based on studies of 4-Factor PCC in animal models of
bleeding51-53 and healthy subjects.44,45,50,54 A retrospective
study of 18 patients treated with rivaroxaban or apixaban
and experiencing traumatic ICH suggested that 4-Factor
PCC reduces hemorrhagic complications and hematoma
expansion.55 In a bleeding model of pigs anticoagulated
with dabigatran, 4-Factor PCC reduced blood loss and therisk of mortality; high-dose 4-Factor PCC resulted in over-
correction of thrombin generation, but no thromboembolic
complications were observed.53 Four-Factor PCC had no
impact on laboratory tests of the anticoagulant action of
dabigatran in a study of nonbleeding healthy subjects (PCC
did not restore aPTT, ECT, or TT) despite evidence that it
improves hemostasis. In the same study, 4-Factor PCC
immediately and completely normalized the prothrombin
time.45 In phase 1 studies of healthy volunteers treated with
edoxaban that underwent punch biopsy, 4-Factor PCC
completely reversed bleeding, restored endogenous
thrombin potential, and partially reversed thrombin time.50
Transient and dose-dependent increases in prothrombin
fragment 1 and 2 (F1þ2) with 3-Factor PCC may reﬂect
possible procoagulant risk.49
Administration of the procoagulant rFVIIa is suggested
for anticoagulated bleeding patients in the U.S. prescribing
information for dabigatran etexilate10 and apixaban.11 In an
ex vivo study of healthy volunteers, rFVIIa normalized
levels of coagulation markers, however, it failed to restore
ﬁbrin generation.56 The impact of this ﬁnding on restoration
of hemostasis is unclear.
Speciﬁc reversal agents are being developed with the
goal of improving the management and outcomes of
bleeding in DOAC-treated patients. In addition to idar-
ucizumab, a speciﬁc reversal agent for dabigatran,57
andexanet alfa is under evaluation for reversal of indirect
or direct FXa inhibitors,58,59 while ciraparantag60 is in
clinical trials for reversal of DOACs as well as other anti-
coagulants. These reversal agents will be discussed in the
papers by Pollack16 and Milling et al17 in this special issue.CONCLUSION
DOACs offer important safety advantages over VKAs
because they are at least as effective for the prevention of
thromboembolism, are associated with lower rates of life-
threatening and intracranial bleeding, and are more
convenient because they can be given in ﬁxed doses without
routine coagulation monitoring. Commonly available gen-
eral coagulation tests have limitations for measurement of
the anticoagulant effects of DOACs. Speciﬁc assays are
commercially available61 but have not been widely imple-
mented. Speciﬁc reversal agents are being introduced into
clinical practice and will help to streamline the management
of patients with bleeding and those who require urgent
surgery.
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